Navigation Links
Amgen And Cytokinetics Announce The First Presentation Of Data From Phase 2 ATOMIC-AHF Study Of Omecamtiv Mecarbil
Date:9/2/2013

avorable dose- and concentration-related trends (nominal p=0.025 and nominal p=0.007, respectively) on dyspnea response. Improvement in dyspnea was observed in the highest omecamtiv mecarbil dose group when compared against its paired placebo group in the third cohort (dyspnea symptom response in 51 percent of subjects on omecamtiv mecarbil versus 37 percent on placebo, nominal p=0.03). The incidence of worsening heart failure within seven days of initiating treatment was 17 percent in the pooled placebo group and was 13 percent, 8 percent and 9 percent on omecamtiv mecarbil in the first, second and third cohorts, respectively. Systolic ejection time, the echocardiographic signature of omecamtiv mecarbil, increased in a concentration-dependent manner.

Rates of adverse events (AEs), serious AEs, adjudicated deaths and hospitalizations were similar between omecamtiv mecarbil and placebo groups. There were seven post-randomization myocardial infarctions in the omecamtiv mecarbil treated groups compared with three in the placebo groups (2.3 percent vs. 1.0 percent, respectively). However, there was no relationship between the maximum increase from the baseline troponin (a biomarker specific for cardiac muscle damage) and increasing plasma concentrations of omecamtiv mecarbil. Omecamtiv mecarbil was not associated with an increased incidence of tachyarrhythmias nor were heart rate or blood pressure adversely affected.

"Although ATOMIC-AHF did not achieve its primary efficacy endpoint, we are encouraged by the data from this study," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "Omecamtiv mecarbil is a unique investigational therapy for patients with acute and chronic heart failure. We look forward to the data from the COSMIC-HF study, which together with the data from ATOMIC-AHF will inform our decisio
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Amgen To Participate At Citis 8th Annual Biotech Conference
2. Healthcare Briefing - Leading Medical Companies in the News: Bio-Solutions, Catalyst Pharmaceutical, MannKind, Amgen, Accuray
3. Amgen to Highlight New Data at Upcoming ESC Congress 2013
4. Acquisition of Onyx Pharmaceuticals, Inc. by Amgen Inc. May Not Be in the Best Interests of Onyx Pharmaceuticals, Inc. Shareholders
5. Amgen To Acquire Onyx Pharmaceuticals For $125 Per Share In Cash
6. Morning Research: BioCryst Pharma Inc., Questcor Pharma Inc., PDL BioPharma Inc., and Amgen Inc.
7. Amgens Second Quarter 2013 Revenues Increased 5 Percent To $4.7 Billion And Adjusted Earnings Per Share (EPS) Increased 3 Percent To $1.89
8. Amgen Announces Webcast of 2013 Second Quarter Financial Results
9. Amgen Award For Science Teaching Excellence Honors Outstanding Teachers
10. Amgen Announces Top-Line Results Of Phase 3 Trebananib (AMG 386) TRINOVA-1 Trial In Recurrent Ovarian Cancer
11. Amgen Presents Positive Results From Talimogene Laherparepvec Phase 3 Study In Patients With Metastatic Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 4, 2015 EspeRare today announced ... Orphan Drug Designation (ODD) for rimeporide, its lead compound ... is a rare, life-threatening disease affecting boys early in ... is the most common and serious form of paediatric ... exchanger type-1 inhibitor, originally developed by Merck Serono in ...
(Date:5/1/2015)... The breakthrough hepatitis C treatment, Sovaldi faced ... Gilead Sciences overcame initial market resistance through its patient ... campaigns. Sovaldi,s high cure rate, short dosing ... the drug to $2.3 billion in sales during the ... the market. But Sovaldi,s price tag of $84,000 was ...
(Date:5/1/2015)... 1, 2015 Hitachi Chemical Diagnostics, Inc. is ... launch of the ExoComplete™ 96-Well Plate Kit and ... for exosome collection to mRNA purification.  The products were ... Annual Meeting, April 23 – 26, 2015, in ... for research use only of molecular biology applications and ...
Breaking Medicine Technology:EspeRare's Investigational Compound Rimeporide Receives European Orphan Drug Designation in Duchenne Muscular Dystrophy 2New Study Examines Success Lessons of Sovaldi's and Harvoni's Blockbuster Launches 2New Products for Exosome Isolation to mRNA Purification 2
... N.J., Oct. 19, 2011 Pacira Pharmaceuticals, Inc. ... data demonstrating a reduction in opioid burdens with EXPAREL™ ... and including 300 mg compared to bupivacaine HCl in ... the American College of Clinical Pharmacy (ACCP) in Pittsburgh. ...
... York eHealth Collaborative (NYeC) today announced the winners of its ... to the world of health information technology and healthcare. The ... NYeC Digital Health Conference 2011 on Thursday, Dec. 1. ... leading the advancement of health IT in New York State," ...
Cached Medicine Technology:Pacira Pharmaceuticals, Inc. Announces New Data Demonstrating Longer Time to First Opioid Use and Reduction in Opioid-Related Adverse Events With EXPAREL™ Compared to Bupivacaine HCl 2Pacira Pharmaceuticals, Inc. Announces New Data Demonstrating Longer Time to First Opioid Use and Reduction in Opioid-Related Adverse Events With EXPAREL™ Compared to Bupivacaine HCl 3Pacira Pharmaceuticals, Inc. Announces New Data Demonstrating Longer Time to First Opioid Use and Reduction in Opioid-Related Adverse Events With EXPAREL™ Compared to Bupivacaine HCl 4Pacira Pharmaceuticals, Inc. Announces New Data Demonstrating Longer Time to First Opioid Use and Reduction in Opioid-Related Adverse Events With EXPAREL™ Compared to Bupivacaine HCl 5Pacira Pharmaceuticals, Inc. Announces New Data Demonstrating Longer Time to First Opioid Use and Reduction in Opioid-Related Adverse Events With EXPAREL™ Compared to Bupivacaine HCl 6New York eHealth Collaborative Announces Winners for its Digital Health Conference Gala Awards 2
(Date:5/4/2015)... CCL, a top-ranked, global provider of ... to other leadership development consultancies. “The CCL Partner ... successful practitioners, expanding our capacity to drive results for ... R. Ryan, CCL President and CEO. , As soon ... Network , it will schedule a one-on-one conference with ...
(Date:5/4/2015)... Diego, CA (PRWEB) May 04, 2015 ... a ribbon cutting ceremony at their brand new, 13,700 ... this year. The new building will not only provide ... population, but will also offer community and educational events ... The new facility is located next door to their ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 Dr. Benjamin ... Georgia proudly offers the latest non-surgical double-chin eliminator. ... facial plastic surgeon in Atlanta to offer Kybella ... to be injected specifically under the chin, promising to ... , Before Kybella, patients who sought immediate solutions for ...
(Date:5/4/2015)... Unlike some camps, the Nike Middle School Running Camps are focused ... educate first and train second, with a significant amount of time ... are building the knowledge base needed to have a long and ... Effort Based Training, Running Heroes, Running Vocabulary, and Why am I ... not a camp where kids come to run and train hard ...
(Date:5/4/2015)... Dr. Richard Champagne, DMD, MAGD is pleased ... the America’s Best Dentist Award, given by the National ... top dentist is a reflection of his vast experience ... compassion for his patients. , Each year, the National ... their field. These nominees are dentists who have exceptionally ...
Breaking Medicine News(10 mins):Health News:The Center for Creative Leadership Is Partnering with Lead Star to Create the CCL Partner Network 2Health News:San Diego Fertility Center Hosted a Ribbon Cutting Ceremony at Its New, Expanded Facility 2Health News:San Diego Fertility Center Hosted a Ribbon Cutting Ceremony at Its New, Expanded Facility 3Health News:Facial Plastic Surgeon First in Atlanta To Offer Kybella Treatments To Reduce Chin Fat 2Health News:US Sports Camps and Select Nike Running Camps Offer Programs for Middle School Runners 2Health News:New Jersey Dentist Dr. Richard Champagne Nominated for America’s Best Dentist Award 2
... a daily basis has been stepped up in China, the ... out breaks of the much dreaded Avian influenza or “bird ... north-west regions two weeks ago. China has accelerated efforts to ... monitoring stations. The public at large and officials have been ...
... with a family history of lung cancer may be at ... new study. // ,Jun-Ichi Nitadori and colleagues at ... they looked into the health of more than 102,000 Japanese ... study, reported the online edition of health magazine WebMD. ...
... Injecting gold into knees affected by osteoarthritis may ease pain and ... it does not help everyone with rheumatoid arthritis. ,Arthritis ... the joints of the body. It is the leading cause of ... arthritis, each of which has a different cause. ,Researchers ...
... to shift gears and use decaffeinated coffee to avoid caffeine ... recent research and data compiled by the University of Florida ... caffeine. ,This month's Journal of Analytical Toxicology. has ... ,coffee which is one of the most prominent sources of ...
... all Public Offices across Bangkok the capital city of ... a senior official from the Bangkok Metropolitan Administration. ... Thai News Agency that the initial reforms have been ... BMA’s headquarters where smoking has already been prohibited in ...
... new survey showed that the total spending on Medicaid has ... was a reflection of a better economy// that has held ... federal Medicare drug benefit, according to a new survey. ,Medicaid ... has shown a growth of 2.8 percent in fiscal 2006, ...
Cached Medicine News:Health News:Decaffeinated Coffee... Not Really! 2Health News:Lowest Spending growth in US Medicaid 2
Straight shafts with 5.5 mm tying platform and 1 mm crisscross serrated tips. Wide serrated handle with polished finish....
Smooth pointed tips open to 3.0 mm. 45 degree cross action angled shafts. Tip to Angle Length: 12.0 mm. Round handle....
Flat handle 9 mm wide, angulated 45....
Straight shafts with pointed tips and 6 mm tying platform. Smooth handle with dull finish. Fine pointed tips....
Medicine Products: